Beyond Air, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Beyond Air, Inc. (XAIR) on November 15, 2021, covering events occurring on November 10, 2021. The Company is an emerging growth company incorporated in Delaware, focused on the development of the LungFit PH product.
Key Financial Metrics and Material Changes
The filing details the termination of a material definitive agreement regarding a credit facility. No specific revenue, profit, or cash flow figures are provided within the text of this 8-K; financial results for the fiscal quarter ended September 30, 2021, are referenced in an attached press release (Exhibit 99.1) but not detailed in this document.
- Debt Reduction: The Company terminated a Facility Agreement with certain lenders on November 10, 2021.
- Loan Details: The agreement originally provided for up to $25,000,000 in five tranches. Only the first tranche of $5,000,000 had been borrowed as of March 17, 2020.
- Terms: The outstanding loan bore interest at 10% per year. Repayment was originally scheduled to commence on June 15, 2023, with a maturity date of March 17, 2025.
- Termination Terms: In October 2021, the Company amended the agreement to allow for the redemption of the $5,000,000 outstanding balance and termination of the facility without penalty.
Guidance, Outlook, and Risks
The filing does not contain new management guidance, outlook, or risk factors beyond the context of the debt termination. The original Facility Agreement included a contingency where Tranches Three through Five were contingent upon FDA approval of the LungFit PH product; however, the termination of the agreement removes this future funding mechanism.
Investor Verification Checklist
- Verify the exact cash outflow required to redeem the $5,000,000 principal and any accrued interest as of the November 10, 2021 termination date.
- Review the attached Press Release (Exhibit 99.1) for the specific revenue, net loss, and cash position for the quarter ended September 30, 2021.
- Confirm the Company's current liquidity position following the debt repayment to assess runway for ongoing operations.
- Monitor the status of the LungFit PH product FDA approval, as the terminated facility was previously tied to this milestone for future funding.